Search

everythinglearnresearchcommunity

for

Search:↓

A trans woman experiencing male pattern baldness has been using Minoxidil and microneedling for 3.5 months, noticing visible hair regrowth. Despite initial skepticism, progress is evident, though a hair transplant might be needed for fuller coverage.

The user has been using topical minoxidil for 4 months and switched to oral minoxidil, considering adding finasteride for better results. They are advised to aggressively treat hair loss with minoxidil for regrowth and finasteride for prevention, while monitoring for side effects.

The conversation discusses hair regrowth and miniaturization, with the user transitioning to oral dutasteride and oral minoxidil, and occasionally using topical minoxidil. The user observes baby hairs near the hairline but less on the scalp, indicating possible regrowth and shedding.

A 36-year-old male has been using 1 mg finasteride for 2 years and recently switched to dutasteride for 3.5 months, noticing stable hair with slight thickening and no significant side effects. Other users discuss their experiences with finasteride, minoxidil, and dutasteride, with some reporting no results or side effects.

The user experienced significant hair regrowth after switching from finasteride to dutasteride and from topical to oral minoxidil, despite some patchiness along the hairline. The user reduced the oral minoxidil dose due to low blood pressure concerns.

Using finasteride and minoxidil for six months led to improved hair density and appearance. A temporary decrease in libido was noted as a side effect.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation discusses creating a foam version of RU58841 for easier application on thick hair, comparing it to minoxidil foam. The user currently uses dutasteride, minoxidil, and needling for hair loss treatment.

The user changed their hair loss treatment to 5mg oral Minoxidil and 2.5mg Dutasteride daily, resulting in significant hair regrowth over two months. They also used Nizoral 2% Ketoconazole shampoo to improve scalp health.

A 22-year-old trans woman has been on 6mg estradiol enanthate for five months. She reports thicker and healthier hair but not much regrowth yet.

Switching from finasteride to dutasteride for hair loss treatment. Dutasteride is suggested as a more effective alternative.

Topical spironolactone 5% is being discussed for its effectiveness in treating hair loss, specifically receding temples. The user is inquiring if it works similarly to finasteride as a testosterone blocker.

The user is taking 1mg finasteride daily and RU58841 5% but still experiencing hair loss. They are considering adding topical finasteride or switching to dutasteride, and are not planning to use minoxidil until hair loss stabilizes.

A user shared their positive experience with hair loss treatment, using 0.5 mg of oral dutasteride daily for a year after switching from 1 mg of finasteride and topical minoxidil. They also mentioned the benefits of oral minoxidil over topical application and the use of ketoconazole shampoo.

User switched from finasteride to combination dutasteride and finasteride for hair density improvement. They noticed less hair shedding and more youthful skin, with a reply suggesting less DHT could increase elastin in skin.

The post and conversation are about skepticism towards HairClone's crowdfunding campaign for a hair loss cure, with users expressing doubt and calling it a scam. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.

The user, a 27-year-old male, has been treating early hair loss with topical finasteride and minoxidil, then switched to oral finasteride and dutasteride, but has seen no improvement and plans to add oral minoxidil. Despite treatment, hair loss has progressed from Norwood 1-1.5 to Norwood 3, with noticeable thinning, especially on the left side.

The user started with Finasteride at 19, added Dutasteride and Minoxidil at 26, but continues to experience hair loss. Suggestions include checking health markers, considering genetics, and possibly increasing Minoxidil dosage.

The user is experiencing progress in hair regrowth using 1 mg finasteride and 5 mg minoxidil, with no side effects reported. There is a discussion about whether to switch from finasteride to dutasteride, but many advise against it since finasteride is showing good results.

Tapering off minoxidil from 5% to 2% and gradually reducing frequency may help minimize hair loss, but some loss might be unavoidable. The discussion focuses on managing hair loss when discontinuing minoxidil.

The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.

OP plans to switch from topical to oral minoxidil due to limited results and is advised to overlap both for a few weeks before discontinuing the topical. Oral minoxidil may be more effective for non-responders to topical treatment.

Hair restoration after FUE surgery, with discussions on using finasteride, dutasteride, and oral minoxidil for hair maintenance and growth. Users share experiences with these treatments, noting varying side effects and effectiveness.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Switching from finasteride to dutasteride led to hairline regression and scalp issues for some users, prompting a return to finasteride. Users reported better maintenance and regrowth with finasteride compared to dutasteride, despite using oral minoxidil throughout.

Hair loss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

A user is seeking advice on obtaining oral minoxidil in Australia through telehealth services. They are considering options like Mosh and are unsure if they should mention previous use or claim it's for hypertension.